5-Amino-1MQ Research Guide UK 2026: NNMT Inhibition & Metabolic Studies

This guide reviews the current state of 5-Amino-1MQ research for laboratory and research professionals in the UK as of 2026. It is provided for research context only. 5-Amino-1MQ is supplied strictly for in vitro research and laboratory use; it is not approved for human or veterinary use, and nothing below describes or recommends any form of administration to people.

Key Takeaways

5-Amino-1MQ is a small molecule that inhibits the NNMT enzyme, a regulator studied in cellular energy and methylation pathways.
Preclinical studies in animal models have reported associations with metabolic and adipose-tissue endpoints; no human trial data exists.
5-Amino-1MQ is sold as a research chemical and is not approved for human use by any regulatory body.
Its distribution in the UK falls into a gray market, raising documented concerns about purity, composition, and supplier quality control.
No human dosing, cycling, or combination protocols have been established; parameters used in animal studies are not validated for human use.

What Is 5-Amino-1MQ

5-Amino-1MQ is a small molecule — not a peptide — developed to target an enzyme called nicotinamide N-methyltransferase (NNMT). NNMT is studied as a regulator of how cells handle energy substrates and methyl-group transfer.

5-Amino-1MQ is a selective inhibitor of the NNMT enzyme. By blocking NNMT activity, it has been investigated for its influence on cellular metabolism. Researchers initially examined it in the context of obesity and metabolic-syndrome research models, exploring whether modulating NNMT alters markers of substrate utilisation and energy expenditure.

In brief:

Chemical nature: a synthetic organic compound, a methylquinolinium salt.
Primary action: inhibition of the NNMT enzyme.
Research focus: initially explored in obesity and metabolic-syndrome models.

It is not a prescribed medicine. It is a research compound studied in laboratory settings and supplied by research chemical vendors strictly for research use only. Nexyra Lab supplies this compound at high purity for scientific work.

5-Amino-1MQ targets NNMT, an enzyme that consumes S-adenosylmethionine (SAM), the cell's principal methyl donor. When NNMT is highly active, it draws on SAM and can lower available NAD⁺. In research models, inhibiting NNMT has been associated with preserved SAM and NAD⁺ availability, which is the mechanistic basis for studies into cellular energy and substrate handling.

Although it is not approved for human use by any major regulatory body, interest in NNMT inhibition as a research target has driven study of 5-Amino-1MQ in metabolic models. It is available in different forms and quantities from research suppliers for research purposes only.

How 5-Amino-1MQ Works

5-Amino-1MQ acts by inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme expressed in tissues including adipose, liver, and muscle.

NNMT transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide (a form of vitamin B3), producing 1-methylnicotinamide. Because SAM is also required for many other methylation reactions, including gene-expression regulation, high NNMT activity draws heavily on SAM and is associated in studies with reduced NAD⁺, a coenzyme central to cellular energy production.

In research models, elevated NNMT activity has been associated with:

lower NAD⁺ levels, with downstream effects on mitochondrial energy production;
a shift toward fat storage in adipose tissue;
reduced metabolic rate.

By inhibiting NNMT, 5-Amino-1MQ has been studied for its effect on preserving NAD⁺ availability. In animal models, this preservation was associated with increased fat oxidation relative to storage. This mechanism underlies the compound's use in metabolic-efficiency research.

In mechanistic terms, 5-Amino-1MQ is studied as a means of conserving cellular SAM and NAD⁺ that would otherwise be consumed by NNMT activity — a pathway of interest in energy-metabolism and adipose-tissue research.

Research has reported that blocking NNMT was associated with increased energy expenditure and reduced fat mass in animal studies, independent of diet or exercise changes. These findings are the basis for continued investigation of the pathway in metabolic models.

NNMT Inhibition Mechanism

The compound's activity centres on blocking NNMT, found in various tissues including adipose. NNMT transfers a methyl group from SAM onto nicotinamide, producing 1-methylnicotinamide while consuming methyl donors and contributing to NAD⁺ depletion.

When NNMT activity is high, research models report:

reduced NAD⁺ availability for mitochondrial energy production;
a tendency toward increased fat storage;
a lower overall metabolic rate.

By inhibiting NNMT, 5-Amino-1MQ has been associated with reduced NAD⁺ depletion in research models. In rodent studies, NNMT inhibition was associated with shifts in metabolic substrate utilisation. The quinolinium structure of 5-Amino-1MQ is designed to fit the NNMT active site selectively, which is significant because SAM is used by many other enzymes that researchers do not intend to affect.

5-Amino-1MQ selectively blocks NNMT, preventing methyl-group transfer and, in research models, helping preserve SAM and NAD⁺ availability. This shift in cellular chemistry is associated in rodent studies with altered substrate utilisation.

Conceptually, NNMT acts as a metabolic brake in these models, and 5-Amino-1MQ is studied as an inhibitor that releases it. This targeted mechanism is central to its role in metabolic research.

NNMT Overexpression In Obesity

Research consistently reports that NNMT activity is elevated in obesity. In lean subjects, NNMT activity in adipose tissue tends to be low; in those carrying excess weight, particularly central adiposity, NNMT levels in white adipose tissue and liver are markedly higher.

Lean subjects: low NNMT activity in adipose tissue.
Subjects with obesity: significantly higher NNMT activity in adipose tissue and liver.

Studies in hundreds of participants have found that higher blood levels of 1-methylnicotinamide (a marker related to NNMT activity) correlated with greater NNMT in adipose tissue, and were inversely related to insulin sensitivity. When insulin sensitivity improved through exercise or bariatric surgery, NNMT levels in adipose tissue fell — suggesting NNMT activity tracks with metabolic state rather than being a passive marker.

The evidence positions NNMT as an active participant in the metabolic changes seen in obesity. Whether reducing NNMT activity would directly reverse these changes in humans remains an open research question; the consistent association is what makes the pathway an interesting target, including for compounds such as 5-Amino-1MQ.

Cell-culture research has shown that reducing NNMT was associated with less lipid accumulation in fat cells, while increasing NNMT was associated with more — suggesting NNMT contributes to adipocyte function rather than simply marking metabolic dysfunction. Elevated NNMT is a consistent feature in obesity research across species, making it a key area of preclinical investigation.

Preclinical Efficacy Studies

Most available data on 5-Amino-1MQ comes from rodent studies, which are not directly translatable to humans.

A 2018 study reported that administering 5-Amino-1MQ to diet-induced obese mice, at the dose defined in the study protocol over an 11-day period, was associated with reduced body weight, decreased adipose mass, and lowered plasma cholesterol — without reduced food intake, pointing to altered energy handling. It was among the first reports of a small molecule reproducing the metabolic effects seen with earlier NNMT-blocking approaches.

Reported endpoints from that study:

Body weight: significantly reduced (p < 0.05).
White adipose mass: decreased (p < 0.01).
Plasma total cholesterol: lowered (p < 0.05).
Adipocyte size: reduced (p < 0.0001).

These results are from short-duration rodent studies and do not indicate that comparable outcomes occur in humans.

Later work examined NNMT inhibition combined with dietary changes in obese mice, reporting reductions in body weight, fat mass, and hepatic fat, alongside shifts in gut bacterial populations. A separate 2019 study in older mice reported that NNMT inhibition was associated with how muscle stem cells supported regeneration in rodent models — a different research angle from the metabolic work. All of these findings are in rodents, and their relevance to humans is unestablished.

Comparison To NAD+ Precursors

5-Amino-1MQ is often compared with NAD⁺ precursors such as NMN and NR. Both relate to NAD⁺ metabolism but through different mechanisms.

NAD⁺ precursors (nicotinamide riboside, nicotinamide mononucleotide) work by directly supplying building blocks for NAD⁺ synthesis. The rationale is that NAD⁺ levels decline with age, affecting cellular energy production. Human evidence for precursors is mixed: some trials report good safety, but metabolic endpoints such as insulin sensitivity have not consistently replicated in people.

Whereas NAD⁺ precursors aim to increase NAD⁺ directly, 5-Amino-1MQ takes a different route by inhibiting NNMT. In research models, this inhibition indirectly preserves NAD⁺ by reducing methylation of nicotinamide, and also maintains SAM levels — an effect precursors do not address.

By blocking NNMT, 5-Amino-1MQ has been studied for its role in conserving nicotinamide for NAD⁺ production while maintaining SAM. This dual mechanism distinguishes it from precursor supplementation in research terms.

NAD⁺ precursors (NMN, NR): directly raise NAD⁺; provide synthesis building blocks; inconsistent human metabolic results.
5-Amino-1MQ: inhibits NNMT; indirectly preserves NAD⁺; maintains SAM; in models, associated with adipose fat oxidation.

The two strategies are not interchangeable; 5-Amino-1MQ is studied as a more indirect approach acting on NNMT, with downstream effects on NAD⁺ and methylation, rather than adding precursors to the system. Related pathways are explored in NAD⁺ research.

Comparison To Semaglutide And Tirzepatide

Compared with semaglutide and tirzepatide, 5-Amino-1MQ operates through an entirely different mechanism. Semaglutide and tirzepatide are GLP-1 receptor agonists (tirzepatide also targeting GIP), mimicking gut hormones that regulate satiety and blood sugar — a well-established pathway with extensive human data.

5-Amino-1MQ works through NNMT inhibition: not hormone mimicry, but modulation of cellular methylation and substrate handling. Crucially, semaglutide and tirzepatide have extensive human clinical-trial data and regulatory approval for specific conditions, whereas 5-Amino-1MQ remains a research compound with preclinical data primarily from animal studies.

Mechanism — semaglutide/tirzepatide: GLP-1 (and GIP) receptor agonism; 5-Amino-1MQ: NNMT inhibition.
Human data — semaglutide/tirzepatide: extensive, approved for type 2 diabetes and obesity; 5-Amino-1MQ: primarily rodent studies, no published human trials.
Target pathway — semaglutide/tirzepatide: gut-brain axis, insulin secretion, appetite; 5-Amino-1MQ: cellular methylation, SAM levels, adipose energy expenditure.

Comparing efficacy on the basis of preclinical 5-Amino-1MQ data would be misleading; the path from rodent studies to validated human outcomes is long and uncertain. For context, retatrutide, another metabolic-pathway compound, operates on different receptor systems again.

These compounds are not interchangeable even where outcomes might overlap: one targets hormonal signalling, the other fundamental cellular metabolism. The distinction matters when considering the research required to validate any of them.

Human Genetic Data On NNMT

Genetic research has linked variation in the NNMT gene to traits such as body mass index and resting energy expenditure. Studies in a Mexican population, for example, identified associations between specific NNMT variants and these metabolic traits, suggesting NNMT-related DNA differences track with energy handling.

Beyond sequence, epigenetic evidence points to an NNMT-linked signature in human adipose tissue, indicating the pathway is dynamically active in human fat biology, not only in laboratory animals.

The key takeaway from human genetic and epigenetic data is that the NNMT axis is biologically active and relevant to human metabolism.

Gene variants: specific NNMT variants associated with BMI and resting energy expenditure in human studies.
Epigenetic signatures: NNMT expression changes observed in human adipose tissue.
Metabolic phenotype: these factors correlate with observable metabolic characteristics.

These are associations rather than proof that altering NNMT activity reverses metabolic changes, but they motivate continued research into NNMT inhibitors in metabolic models.

Epigenetic Signatures In Adipose Tissue

Adipose tissue is metabolically active, and its behaviour can be influenced by epigenetic modifications — changes that switch genes on or off without altering the underlying sequence. Research has examined how NNMT may participate in such changes within adipose tissue.

Studies suggest a link between NNMT gene expression and specific epigenetic patterns in fat cells. High NNMT, as often seen in obesity, may be associated with marks favouring fat storage; reduced NNMT may shift these patterns toward a more metabolically active state. This is explored in research on the effects of NNMT knockdown in fat and liver tissue.

NNMT and lipid accumulation: in cell studies, reducing NNMT was associated with less stored fat; increasing it, with more.
Glucose influence: glucose availability affects NNMT production in fat cells, linking activity to the nutrient environment.
Adipose identity: NNMT appears involved in adipocyte development, not merely a marker.
Hormonal pathways: evidence suggests NNMT influences pathways controlling adipocyte differentiation.

NNMT's potential role in epigenetic regulation within adipose tissue is a significant research area, with implications for understanding how metabolic states develop. The work remains early-stage.

These signatures help researchers understand how diet and weight can leave lasting marks on adipose function. Related reproductive-biology effects of NNMT inhibition are also under investigation, with some studies noting effects on embryo implantation in models.

Structure-Activity Relationship Studies

Structure-activity relationship (SAR) studies examine how changes to a molecule's structure affect its function. For 5-Amino-1MQ, this work has mapped which parts of the molecule are most important for inhibiting NNMT.

Researchers have explored modifications to the quinolinium core. Altering substituents on the aromatic rings can significantly change binding affinity to NNMT; the methyl group at the 1-position and the amino group at the 5-position appear important for inhibitory activity.

Quinolinium ring system: core structure for interacting with the enzyme's active site.
Amino group (position 5): appears central to binding and inhibition.
Methyl group (position 1): also important for effective inhibition.
Other substituents: modifications can fine-tune potency and selectivity, potentially reducing off-target activity.

The research goal is potent, selective NNMT inhibitors with favourable selectivity profiles. Early work, including in the Journal of Medicinal Chemistry, has mapped these relationships to guide the design of next-generation NNMT inhibitors.

SAR work functions as a blueprint for compound design, identifying which structural features drive activity and which can be modified. This systematic approach guides how candidate compounds advance in research.

Theoretical Concerns From Mechanism

While NNMT inhibition is a promising research target, the mechanism raises points that warrant caution in interpretation. Blocking NNMT is expected to raise SAM availability, but SAM participates in many cellular processes, so research must establish that selectively raising it does not perturb other methylation pathways.

SAM's many roles: SAM is the primary methyl donor, used in DNA/RNA methylation, protein modification, and synthesis of neurotransmitters and hormones.
Potential off-target effects: broad changes to methylation could, in theory, affect gene expression in ways not yet characterised.
The NAD⁺ connection: sustained NAD⁺ availability from NNMT inhibition has downstream effects that are not fully mapped across cell types.

The concern is not that 5-Amino-1MQ is inherently hazardous, but that understanding of the methylation network is still developing. Modulating a complex system carries the possibility of unintended effects that require careful study.

Some studies suggest the quinolinium structure is sufficiently NNMT-selective that it should not broadly deplete SAM, but the wider metabolic picture remains an active research consideration. Other metabolic regulators such as MOTS-c carry their own theoretical considerations in research.

Gut Microbiome Effects

Research suggests compounds such as 5-Amino-1MQ may alter the gut microbiome in models. One study in diet-induced obese mice found that an NNMT inhibitor combined with a calorie-restricted diet was associated with shifts in gut bacterial populations, suggesting metabolic intervention can have knock-on effects on gut composition.

The implications of these changes for human health remain unclear, but it is an active research area.

Altered bacterial composition: changes in bacterial types and amounts observed after NNMT inhibition in models.
Metabolic by-product changes: shifts in bacteria can influence microbial metabolites that affect host metabolism.
Possible combination research: co-study with probiotics has been proposed, though this is speculative.

Interventions affecting systemic metabolism, such as NNMT inhibition, are likely to influence the gut microbiome. Characterising this bidirectional relationship is an open research question, and the work is early-stage.

NNMT In Cancer Biology

NNMT is relevant to cancer biology as a research consideration. NNMT is expressed in some cancer cells, which makes interpretation of inhibition complex: effects could differ by cancer type or stage, and the data are largely from models rather than long-term human study.

NNMT participates in methylation processes that influence cell behaviour, including growth and division. Modulating these pathways is therefore an area requiring careful characterisation in research.

Limited long-term data: most evidence is from animal models, with no long-term human study of NNMT inhibition and oncological endpoints.
NNMT expression in cancers: NNMT is overexpressed in certain cancers; how inhibition affects these is not well characterised.
Methylation alterations: changing methylation balance could influence DNA stability and proliferation, key factors studied in cancer biology.

The relationship between NNMT inhibition and cancer biology is currently understood largely at a theoretical and preclinical level. Because human data are limited, any influence on malignancy-related processes remains an area requiring significant further research — one reason the compound is restricted to experimental settings.

Absence Of Human Safety Data

There is currently no published human safety data for 5-Amino-1MQ. Available information derives from animal studies or from mechanistic reasoning. Any extrapolation to humans is unsupported by clinical evidence.

Because the compound is unproven in people and material sold as a research chemical is not manufactured to pharmaceutical standards, the full profile of potential effects is uncharacterised. Mechanism-based research considerations include:

Altered methylation: NNMT inhibition affects SAM, a participant in many methylation reactions; the consequences of sustained elevated SAM across cell types are not characterised.
Signalling-molecule effects: 1-methylnicotinamide is itself a signalling molecule; altering its production may affect downstream pathways in ways not yet studied long-term.
Gut microbiome changes: rodent studies indicate altered gut bacteria, with unknown relevance to humans.

It is also worth noting what research does not exist: there are no reproductive- or developmental-toxicology studies, no studies in hepatic or renal impairment, and no drug-interaction studies for 5-Amino-1MQ. These are gaps in the research record, not established safety findings.

The absence of human trials means safety is uncharacterised. Theoretical concerns are not proof of harm, but they identify areas — off-target SAM effects, signalling-pathway impacts, and uncharacterised interactions — that require study before any conclusion about human safety could be drawn.

No Established Human Protocols

Human dosing, cycling, and combination protocols have not been established for 5-Amino-1MQ. Parameters reported in animal studies are specific to those study designs and are not validated for human use. No clinical data supports any administration regimen, schedule, or combination with other compounds.

Material discussed in non-research contexts that describes use regimens or compound "stacks" is not derived from clinical evidence and falls outside the scope of legitimate research. 5-Amino-1MQ is supplied for in vitro and laboratory research only.

Regulatory Status UK 2026

As of 2026, 5-Amino-1MQ is not approved for human use by any UK health authority. It is not available as a medicine or as a dietary supplement. It remains a research-phase compound that has not undergone the testing required to establish safety and efficacy in people.

It is therefore not sold in pharmacies or health-food retail. Its only lawful availability is for laboratory research purposes.

Not approved for human consumption.
Sold strictly for laboratory research.
No official human safety or efficacy data.

For researchers who are also competitive athletes, note that compounds not approved for human use can fall under broad anti-doping categories even where not specifically named. 5-Amino-1MQ remains firmly in the research category, with no clear timeline for any UK approval.

Because the compound lacks regulatory approval, any product marketed for human use is being sold through unofficial channels that do not meet pharmaceutical manufacturing standards, raising documented concerns about purity, composition, and contamination.

Gray-Market Distribution

As an unapproved compound, 5-Amino-1MQ is largely distributed through the "gray market" — research-chemical vendors rather than pharmaceutical firms, typically labelled for research use only. The central issue is the absence of oversight on what is actually supplied.

Purchasing from unverified vendors carries documented risk: no guarantee of purity, composition consistency, or absence of contaminants — far from the standards expected of regulated products. This is why sourcing diligence and independent verification matter for research-grade material.

Purity and contamination: supplied material may not match its label or may contain other substances.
Composition inconsistency: the amount of compound per unit can vary between batches.
Lack of verification: no independent body routinely checks gray-market products.

While the science behind NNMT inhibition is of genuine research interest, current gray-market distribution means buyers without independent verification cannot be confident in what they receive. This is the gap between promising preclinical research and verifiable, quality-controlled supply — and the reason a published Certificate of Analysis per batch matters.

Approval Status And Future Outlook

In mid-2026, 5-Amino-1MQ remains in the research phase. It has not progressed through regulatory channels, there are no approved human uses, and no registered clinical trials exist for it. It has moved from academic laboratories into research-chemical supply, labelled for research use only.

The path from research compound to approved medicine is long, costly, and uncertain. For 5-Amino-1MQ to be considered for human use, it would require extensive preclinical safety testing followed by multiple phases of human trials — a process typically led by pharmaceutical developers, none of whom have publicly committed to it.

There is genuine academic interest in targeting NNMT for metabolic research, but whether this becomes a formal clinical programme for 5-Amino-1MQ specifically is unclear; future development may instead involve next-generation inhibitors.

Current status: preclinical research compound, not approved for human use.
Regulatory pathway: no IND application filed, no clinical trials registered.
Future development: dependent on pharmaceutical investment and successful human trials.

Compounds like this are of research interest but are not proven therapies. The scientific community continues to study NNMT inhibition, but for now 5-Amino-1MQ remains a subject of laboratory investigation.

Legal Considerations UK

In the UK, 5-Amino-1MQ is not approved by any health authority for human use. It is not sold in pharmacies or as a medicine; it is available through channels labelled strictly for research purposes. This classification means it has not undergone the safety and efficacy testing required of medicines.

Research-chemical status: compounds like 5-Amino-1MQ are typically sold for laboratory use only, not for human consumption.
No human approval: there are no official human guidelines, because the compound is unapproved.
Importation: import rules may apply depending on quantity and declared purpose; current customs regulations should be checked.

The regulatory landscape for novel compounds shifts over time. Material permissible for research today could face stricter controls if it appears in non-research contexts. Staying current with regulatory updates is advisable.

For competitive athletes, the World Anti-Doping Agency's "Non-Approved Substances" category (S0) can apply to compounds not approved for human use even where not individually listed. 5-Amino-1MQ is sold as a research chemical and should be treated as such.

Conclusion

NNMT inhibition, including with 5-Amino-1MQ, is a rapidly evolving research area. While preclinical studies report associations of interest for metabolic research, human data are absent. Current availability is confined to the research-chemical market, without regulatory oversight or established human safety data. As research progresses, regulated pharmaceutical development may eventually offer validated pathways for NNMT inhibitors; until then, the compound remains a subject of laboratory investigation, supplied strictly for research use only.

Frequently Asked Questions

What exactly is 5-Amino-1MQ?

5-Amino-1MQ is a small synthetic chemical compound, not a peptide. It is studied for its ability to inhibit an enzyme called NNMT, which research links to cellular energy handling and methylation.

What does NNMT inhibition do in research models?

In animal studies, inhibiting NNMT has been associated with altered energy handling in fat cells and with preserved SAM and NAD⁺ availability. These observations are largely from rodent models and have not been demonstrated in humans.

Is 5-Amino-1MQ approved for use in the UK?

No. As of 2026, 5-Amino-1MQ is not approved by any health authority, including the MHRA. It is classified as a research chemical, intended only for laboratory research and not for human use.

Why does sourcing matter for research-grade 5-Amino-1MQ?

Because the compound is sold on the gray market without routine independent oversight, purity and composition can vary between suppliers. For research use, material backed by independent HPLC verification and a published batch Certificate of Analysis provides documented confidence in what is supplied.

What are the gaps in 5-Amino-1MQ research?

There is no published human safety or efficacy data, no reproductive- or developmental-toxicology research, no studies in hepatic or renal impairment, and no drug-interaction studies. The research record is based on animal models and mechanistic reasoning.

Are human dosing or combination protocols established?

No. No human dosing, cycling, or combination protocols have been established. Parameters used in animal studies are specific to those study designs and are not validated for human use.